We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Cencora, Inc. (COR)

NYSE - NYSE Delayed Price. Currency in USD
Visitors trend2W10W
234.00-1.64 (-0.70%)
At close: 04:00PM EDT
234.00 0.00 (0.00%)
After hours: 04:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close235.64
Open235.00
Bid230.31 x 900
Ask256.88 x 800
Day's Range233.10 - 236.24
52 Week Range163.37 - 246.75
Volume822,327
Avg. Volume1,243,088
Market Cap46.629B
Beta (5Y Monthly)0.47
PE Ratio (TTM)25.52
EPS (TTM)9.17
Earnings DateMay 01, 2024
Forward Dividend & Yield2.04 (0.87%)
Ex-Dividend DateFeb 08, 2024
1y Target Est254.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for COR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cencora, Inc.
    Analyst Report: Cencora IncHeadquartered in Conshohocken, Pennsylvania, Cencora, formerly AmerisourceBergen, is one of the nation's largest pharmaceutical distributors. The company distributes brand-name and generic pharmaceuticals, over-the-counter (OTC) healthcare products, and home healthcare supplies and equipment to healthcare providers throughout the U.S. It also provides pharmaceuticals and pharmacy services to patients requiring specialty drugs such as immunology and oncology treatments. Cencora has international operations through its World Courier logistics business and assets acquired from Alliance Healthcare and PharmaLex.
    Rating
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • Business Wire

    Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release

    CONSHOHOCKEN, Pa., April 05, 2024--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 1, 2024.

  • Zacks

    Here's Why Cencora (COR) is a Strong Value Stock

    Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

  • Zacks

    Are Medical Stocks Lagging Artivion (AORT) This Year?

    Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

  • Zacks

    Why Cencora (COR) is a Top Growth Stock for the Long-Term

    Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

  • Business Wire

    Cencora Announces Leadership Succession Plan

    CONSHOHOCKEN, Pa., March 12, 2024--Cencora, Inc. (NYSE: COR) today announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024. Robert P. Mauch, PharmD, PhD, current Chief Operating Officer of Cencora, will succeed Collis as President and CEO, and will also be appointed as a member of the Company's Board, effective the same date.

  • Zacks

    Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

    Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

  • Reuters

    Walgreens Boots pockets $992 million after cutting Cencora stake for third time

    The proceeds include around $942 million from shares sold as well as about $50 million from a concurrent share repurchase by Cencora, formerly AmerisourceBergen. Walgreens has been grappling with waning demand for COVID-19 vaccines and testing as well as decreased spending on personal care and beauty products by inflation-weary consumers. It said it now owns around 13% of Cencora's common stock from 15% previously, and that it would use the sale proceeds primarily to pay down debt.

  • Business Wire

    Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

    CONSHOHOCKEN, Pa., February 07, 2024--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.

  • Business Wire

    Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds

    DEERFIELD, Ill., February 07, 2024--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of approximately $942 million and, subject to the completion of the Rule 144 sale, a concurrent share repurchase by Cencora in the amount of approximately $50 million.

  • Business Wire

    Cencora Closes $500 Million Senior Notes Offering

    CONSHOHOCKEN, Pa., February 07, 2024--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the "Notes"), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the "SEC") on November 23, 2021.